---
title: GLP1 and novel medications for obesity and diabetes
videoId: C5KpIXjpzdY
---

From: [[hubermanlab]] <br/> 
Glucagon-like peptide-1 (GLP-1) has emerged as a pivotal player in the treatment of diabetes and obesity, offering promising interventions that extend beyond traditional medication mechanisms. GLP-1 is a hormone that plays a role in glycemic control and appetite regulation, making it an appealing target for developing novel therapeutics for metabolic disorders. This article explores the development, function, and implications of GLP-1 and related medications in managing obesity and diabetes.

## Discovery and Function of GLP-1

The interest in GLP-1 began with the identification of incretin hormones, which enhance insulin secretion in response to meals. The incretin effect, observed as early as the 1920s, revealed that oral glucose intake stimulates more insulin release than intravenous glucose, implicating gut-derived factors in insulin regulation <a class="yt-timestamp" data-t="01:13:25">[01:13:25]</a>.

GLP-1 is a product of the proglucagon gene, differently processed in various tissues. In the intestine, GLP-1 enhances insulin secretion, slows gastric emptying, and suppresses appetite, offering multifaceted benefits for glucose homeostasis and weight management [[biological_mechanisms_of_hunger_and_satiety | biological mechanisms of hunger and satiety]], which are crucial for effective [[dietary_interventions_for_obesity_and_psychiatric_conditions | dietary interventions]] <a class="yt-timestamp" data-t="01:14:50">[01:14:50]</a>.

## The Evolution of GLP-1-Based Medications

Initial formulations of GLP-1-based therapies faced significant hurdles due to the hormone’s short half-life, approximately 2 minutes in circulation, which limited their practical use. Advances in pharmacology brought about the development of GLP-1 receptor agonists with extended half-lives, such as exenatide—a synthetic version of a GLP-1 analog found in the venom of the Gila monster, boasting a half-life of about 2 hours [[overview_of_peptide_therapeutics | overview of peptide therapeutics]] <a class="yt-timestamp" data-t="01:15:55">[01:15:55]</a>.

Further modifications led to the development of semaglutide, a GLP-1 analog with a half-life stretching to about 7 days, enabling a once-weekly administration schedule. This advancement marked a substantial breakthrough in enhancing compliance and maximizing therapeutic effects, allowing for significant weight loss and improved glycemic control [[impact_of_exercise_and_physical_movement_on_blood_sugar_and_insulin_sensitivity | exercise and physical movement on blood sugar and insulin sensitivity]] <a class="yt-timestamp" data-t="01:18:40">[01:18:40]</a>.

## Surprising Health Benefits

Beyond the expected anti-diabetes effects, GLP-1 analogs like semaglutide (marketed as Ozempic and Wegovy) have been associated with broader health benefits, including cardiovascular protection. Clinical trials have demonstrated reduced rates of major adverse cardiovascular events, thought to be partly due to GLP-1’s anti-inflammatory effects [[role_of_inflammation_in_chronic_disease | role of inflammation in chronic disease]] <a class="yt-timestamp" data-t="01:28:50">[01:28:50]</a>.

Moreover, the drugs' ability to decrease appetite and promote weight loss functions significantly through central nervous system pathways, predominantly influencing the brainstem regions like the nucleus of the solitary tract and area postrema, both critically involved in satiety signaling <a class="yt-timestamp" data-t="01:21:04">[01:21:04]</a>.

## Future Directions and Implications

The burgeoning interest in GLP-1 receptor agonists has sparked significant investment and research from major pharmaceutical companies, spurring the innovation of "GLP-1 plus" therapies. These hybrid medications aim to combine the effects of GLP-1 with other metabolic hormones to further enhance efficacy and patient outcomes. Notably, the development of triple-agonist drugs like AMG 133, which target GLP-1 among other receptors, is underway, showing potential for even greater weight reduction while maintaining tolerability [[sciencebacked_tools_for_metabolic_health | science-backed tools for metabolic health]] <a class="yt-timestamp" data-t="01:31:52">[01:31:52]</a>.

The advent of GLP-1 and combination therapies heralds a new era in treating obesity and diabetes, providing safer, more effective treatment modalities. As research progresses, these medications may not only transform metabolic disease management but also extend the therapeutic landscape to conditions linked with inflammation and cardiovascular risk [[health_benefits_of_timerestricted_eating | health benefits of time-restricted eating]]. Overall, GLP-1 receptor agonists represent a promising frontier in pharmaceutical development with far-reaching implications for public health.